(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1660927

ぶどう膜炎治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Uveitis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 163 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
ぶどう膜炎治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年02月20日
発行: Persistence Market Research
ページ情報: 英文 163 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のぶどう膜炎治療の市場規模は、2025年に8億4,820万米ドルになるとみられ、2025年～2032年の予測期間に7.3%のCAGRで拡大し、2032年には13億8,900万米ドルに達すると予測されています。

ぶどう膜炎は、ぶどう膜に影響を及ぼす炎症性疾患群であり、放置すると視力低下につながる可能性があります。ぶどう膜炎治療市場には、炎症を抑え、免疫反応を制御し、合併症を予防することを目的とした副腎皮質ステロイド、免疫抑制剤、生物学的製剤、その他の治療アプローチが含まれます。自己免疫疾患の有病率の増加、目の健康に関する意識の高まり、治療方法の進歩が市場の成長を後押ししています。病院、眼科クリニック、専門眼科センターがぶどう膜炎治療ソリューションの主なエンドユーザーです。

世界のぶどう膜炎治療市場は、ぶどう膜炎に関連する関節リウマチや強直性脊椎炎などの自己免疫疾患の罹患率の上昇など、いくつかの重要な要因によって推進されています。さらに、TNFα阻害剤やIL-6阻害剤を含む生物学的製剤の進歩により、治療効果が向上し、再発率が低下しています。眼科研究への投資拡大やヘルスケア支出の増加も市場拡大に大きく寄与しています。さらに、ぶどう膜炎に罹患しやすい老年人口の増加が、効果的な治療オプションの需要を促進すると予想されます。

ぶどう膜炎治療市場は、標的治療薬の技術革新、遺伝子ベースの治療法に関する研究の増加、および疾患の早期発見におけるAIの統合により、大きな成長機会をもたらしています。長時間作用型注射剤や徐放性製剤の開発により、患者の服薬アドヒアランスが向上し、頻回投与の負担が軽減されると期待されます。さらに、遠隔医療やデジタルヘルスプラットフォームの拡大により、特に遠隔地におけるぶどう膜炎専門医への患者アクセスが改善されつつあります。製薬企業と研究機関の戦略的提携も、新たな治療法の開発を促進しています。

当レポートでは、世界のぶどう膜炎治療市場について調査し、治療別、疾患別、原因別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 主要な市場動向

第4章 重要成功要因

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 動向

第6章 COVID-19危機- 影響評価

第7章 世界市場の需要見通し、2019年～2032年

  • 過去の市場金額（100万米ドル）分析、2019年～2024年
  • 現在および将来の市場金額（100万米ドル）予測、2025年～2032年

第8章 世界市場の見通し、治療別、2019年～2032年

  • 過去の市場規模（100万米ドル）分析、治療別、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、治療別、2025年～2032年
  • 治療別市場の魅力分析

第9章 世界市場の見通し、疾患別、2019年～2032年

  • 過去の市場規模（100万米ドル）分析、疾患別、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、疾患別、2025年～2032年
  • 疾患別市場の魅力分析

第10章 世界市場の見通し、原因別、2019年～2032年

  • 過去の市場規模（100万米ドル）分析、原因別、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、原因別、2025年～2032年
  • 原因別市場の魅力分析

第11章 世界市場の見通し、流通チャネル別、2019年～2032年

  • 過去の市場規模（100万米ドル）分析、流通チャネル別、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、流通チャネル別、2025年～2032年
  • 流通チャネル別市場の魅力分析

第12章 世界市場の見通し、地域別、2019年～2032年

  • 過去の市場規模（100万米ドル）分析、地域別、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、地域別、2025年～2032年
  • 地域別市場の魅力分析

第13章 北米市場の見通し、2019年～2032年

第14章 ラテンアメリカ市場の見通し、2019年～2032年

第15章 欧州市場の見通し、2019年～2032年

第16章 南アジア市場の見通し、2019年～2032年

第17章 東アジア市場の見通し、2019年～2032年

第18章 オセアニア市場の見通し、2019年～2032年

第19章 中東・アフリカ市場の見通し、2019年～2032年

第20章 市場構造分析

第21章 競合分析

  • 競合ダッシュボード
  • ブランディングとプロモーション戦略
  • 主要開発分析
  • 競合の詳細
    • Allergan, Inc
    • Novartis AG
    • Bausch Health Inc.
    • AbbVie Inc.
    • Tarsier Pharma
    • EyeGate Pharmaceuticals, Inc.
    • Alimera Science Inc
    • Eyepoint Pharmaceutical
    • Santen Pharmaceuticals

第22章 使用される仮定と頭字語

第23章 調査手法

目次
Product Code: PMRREP4430

Persistence Market Research has recently released a comprehensive report on the worldwide market for uveitis treatment. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global uveitis treatment market from 2025 to 2032.

Key Insights:

  • Uveitis Treatment Market Size (2025E): USD 848.2 Million
  • Projected Market Value (2032F): USD 1,389.0 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 7.3%

Uveitis Treatment Market - Report Scope:

Uveitis is a group of inflammatory conditions affecting the uvea, which can lead to vision loss if left untreated. The market for uveitis treatment includes corticosteroids, immunosuppressants, biologics, and other therapeutic approaches aimed at reducing inflammation, controlling immune responses, and preventing complications. The increasing prevalence of autoimmune diseases, growing awareness regarding eye health, and advancements in treatment modalities are fueling market growth. Hospitals, ophthalmology clinics, and specialty eye centers are the key end-users of uveitis treatment solutions.

Market Growth Drivers:

The global uveitis treatment market is propelled by several key factors, including the rising incidence of autoimmune disorders such as rheumatoid arthritis and ankylosing spondylitis, which are linked to uveitis. Additionally, advancements in biologic therapies, including TNF-alpha inhibitors and IL-6 inhibitors, are enhancing treatment efficacy and reducing recurrence rates. Growing investment in ophthalmic research and increasing healthcare expenditure are also major contributors to market expansion. Moreover, the growing geriatric population, which is more susceptible to uveitis, is expected to drive demand for effective treatment options.

Market Restraints:

Despite promising growth prospects, the uveitis treatment market faces challenges related to high treatment costs, limited availability of advanced biologic therapies in emerging economies, and potential side effects associated with long-term corticosteroid use. Regulatory hurdles for new drug approvals and the complexity of uveitis diagnosis further hinder market penetration. Additionally, the lack of awareness and delayed treatment can result in irreversible vision damage, impacting market growth.

Market Opportunities:

The uveitis treatment market presents significant growth opportunities driven by innovations in targeted therapies, increasing research in gene-based treatments, and the integration of AI in early disease detection. The development of long-acting injectables and sustained-release drug formulations is expected to enhance patient adherence and reduce the burden of frequent dosing. Furthermore, the expansion of telemedicine and digital health platforms is improving patient access to uveitis specialists, particularly in remote areas. Strategic collaborations between pharmaceutical companies and research institutions are also fostering the development of novel treatment options.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the uveitis treatment market globally?
  • Which treatment modalities are gaining prominence in uveitis management?
  • How are technological advancements reshaping the competitive landscape of the uveitis treatment market?
  • Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global uveitis treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global uveitis treatment market, including AbbVie Inc., Novartis AG, Pfizer Inc., and Santen Pharmaceutical Co., Ltd., focus on research and development, product innovation, and strategic collaborations to strengthen their market position. These companies are investing in biologic therapies, sustained-release drug formulations, and advanced diagnostic tools to improve treatment outcomes. Additionally, partnerships with healthcare providers and government initiatives for eye disease awareness are driving market expansion.

Key Companies Profiled:

  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • Alimera Sciences, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Eyepoint Pharmaceuticals, Inc.
  • UCB S.A.
  • Johnson & Johnson

Key Segments Covered in Uveitis Treatment Industry Research

By Treatment:

  • Corticosteroids
  • Immunosuppressant
  • Monoclonal Antibodies
  • Cycloplegic Agents
  • Antibiotics
  • Antivirals
  • Antifungal
  • Analgesics

Disease:

  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis

Cause:

  • Infectious Uveitis
  • Non-infectious Uveitis

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Treatment Adoption / Analysis
  • 4.2. Disease Epidemiology
  • 4.3. Pipeline Assessment
  • 4.4. Patient Journey Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Regulatory Scenario

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Global Retinal Disorder Treatment Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rise in Autoimmune Diseases
    • 5.2.2. Rise in Infectious Uveitis
    • 5.2.3. Treatment Adoption Rate
    • 5.2.4. Growing Number of Service Providers
    • 5.2.5. Rise in Infectious Illness Frequency in Developing Nations
    • 5.2.6. Mergers and Acquisitions
  • 5.3. Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Treatment
    • 6.1.2. By Disease
    • 6.1.3. By Cause
    • 6.1.4. By Distribution Channel
    • 6.1.5. By Region
  • 6.2. 2022 Market Scenario

7. Global Market Demand Outlook, 2019 - 2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019 - 2024
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2025 - 2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Outlook, 2019 - 2032

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2019 - 2024
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2025 - 2032
    • 8.3.1. Corticosteroids
    • 8.3.2. Immunosuppressant
    • 8.3.3. Monoclonal Antibodies
    • 8.3.4. Cycloplegic Agents
    • 8.3.5. Antibiotics
    • 8.3.6. Antivirals
    • 8.3.7. Antifungal
    • 8.3.8. Analgesics
  • 8.4. Market Attractiveness Analysis By Treatment

9. Global Market Outlook, 2019 - 2032

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Disease, 2019 - 2024
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease, 2025 - 2032
    • 9.3.1. Anterior Uveitis
    • 9.3.2. Posterior Uveitis
    • 9.3.3. Intermediate Uveitis
    • 9.3.4. Panuveitis
  • 9.4. Market Attractiveness Analysis By Disease

10. Global Market Outlook, 2019 - 2032

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Cause, 2019 - 2024
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Cause, 2025 - 2032
    • 10.3.1. Infectious Uveitis
    • 10.3.2. Non-infectious Uveitis
  • 10.4. Market Attractiveness Analysis By Cause

11. Global Market Analysis Outlook, 2019 - 2032

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019 - 2024
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2025 - 2032
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
    • 11.3.4. Drug Stores
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Outlook, 2019 - 2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019 - 2024
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025 - 2032
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Market Outlook, 2019 - 2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Treatment
    • 13.3.3. By Disease
    • 13.3.4. By Cause
    • 13.3.5. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Treatment
    • 13.4.3. By Disease
    • 13.4.4. By Cause
    • 13.4.5. By Distribution Channel
  • 13.5. Country Level Analysis & Forecast
    • 13.5.1. U.S. Market Analysis
      • 13.5.1.1. . Introduction
      • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.1.2.1. By Treatment
        • 13.5.1.2.2. By Disease
        • 13.5.1.2.3. By Cause
        • 13.5.1.2.4. By Distribution Channel
    • 13.5.2. Canada Market Analysis
      • 13.5.2.1. Introduction
      • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.2.2.1. By Treatment
        • 13.5.2.2.2. By Disease
        • 13.5.2.2.3. By Cause
        • 13.5.2.2.4. By Distribution Channel
  • 13.6. Market Trends
  • 13.7. Key Market Participants - Intensity Mapping
  • 13.8. Drivers and Restraints - Impact Analysis

14. Latin America Market Outlook, 2019 - 2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
        • 14.3.1.4.1. By Treatment
        • 14.3.1.4.2. By Disease
        • 14.3.1.4.3. By Cause
        • 14.3.1.4.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Treatment
    • 14.4.3. By Distribution Channel
  • 14.5. Country Level Analysis & Forecast
    • 14.5.1. Brazil Market Analysis
      • 14.5.1.1. . Introduction
      • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.1.2.1. By Treatment
        • 14.5.1.2.2. By Disease
        • 14.5.1.2.3. By Cause
        • 14.5.1.2.4. By Distribution Channel
    • 14.5.2. Mexico Market Analysis
      • 14.5.2.1. Introduction
      • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.2.2.1. By Treatment
        • 14.5.2.2.2. By Disease
        • 14.5.2.2.3. By Cause
        • 14.5.2.2.4. By Distribution Channel
    • 14.5.3. Argentina Market Analysis
      • 14.5.3.1. Introduction
      • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.3.2.1. By Treatment
        • 14.5.3.2.2. By Disease
        • 14.5.3.2.3. By Cause
        • 14.5.3.2.4. By Distribution Channel
  • 14.6. Market Trends
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Drivers and Restraints - Impact Analysis

15. Europe Market Outlook, 2019 - 2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. France
      • 15.3.1.3. Italy
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. Russia
      • 15.3.1.7. BENELUX
      • 15.3.1.8. Nordic Countries
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By Treatment
    • 15.3.3. By Disease
    • 15.3.4. By Cause
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Treatment
    • 15.4.3. By Disease
    • 15.4.4. By Cause
    • 15.4.5. By Distribution Channel
  • 15.5. Country Level Analysis & Forecast
    • 15.5.1. Germany Market Analysis
      • 15.5.1.1. . Introduction
      • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.1.2.1. By Treatment
        • 15.5.1.2.2. By Disease
        • 15.5.1.2.3. By Cause
        • 15.5.1.2.4. By Distribution Channel
    • 15.5.2. France Market Analysis
      • 15.5.2.1. Introduction
      • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.2.2.1. By Treatment
        • 15.5.2.2.2. By Disease
        • 15.5.2.2.3. By Cause
        • 15.5.2.2.4. By Distribution Channel
    • 15.5.3. Italy Market Analysis
      • 15.5.3.1. Introduction
      • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.3.2.1. By Treatment
        • 15.5.3.2.2. By Disease
        • 15.5.3.2.3. By Cause
        • 15.5.3.2.4. By Distribution Channel
    • 15.5.4. U.K. Market Analysis
      • 15.5.4.1. . Introduction
      • 15.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.4.2.1. By Treatment
        • 15.5.4.2.2. By Disease
        • 15.5.4.2.3. By Cause
        • 15.5.4.2.4. By Distribution Channel
    • 15.5.5. Spain Market Analysis
      • 15.5.5.1. . Introduction
      • 15.5.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.5.2.1. By Treatment
        • 15.5.5.2.2. By Disease
        • 15.5.5.2.3. By Cause
        • 15.5.5.2.4. By Distribution Channel
    • 15.5.6. Russia Market Analysis
      • 15.5.6.1. . Introduction
      • 15.5.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.6.2.1. By Treatment
        • 15.5.6.2.2. By Disease
        • 15.5.6.2.3. By Cause
        • 15.5.6.2.4. By Distribution Channel
    • 15.5.7. Nordic Countries Market Analysis
      • 15.5.7.1. . Introduction
      • 15.5.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.7.2.1. By Treatment
        • 15.5.7.2.2. By Disease
        • 15.5.7.2.3. By Cause
        • 15.5.7.2.4. By Distribution Channel
    • 15.5.8. BENELUX Market Analysis
      • 15.5.8.1. . Introduction
      • 15.5.8.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.8.2.1. By Treatment
        • 15.5.8.2.2. By Disease
        • 15.5.8.2.3. By Cause
        • 15.5.8.2.4. By Distribution Channel
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis

16. South Asia Market Outlook, 2019 - 2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Indonesia
      • 16.3.1.4. Malaysia
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Treatment
    • 16.3.3. By Disease
    • 16.3.4. By Cause
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Treatment
    • 16.4.3. By Disease
    • 16.4.4. By Cause
    • 16.4.5. By Distribution Channel
  • 16.5. Country Level Analysis & Forecast
    • 16.5.1. India Market Analysis
      • 16.5.1.1. . Introduction
      • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.1.2.1. By Treatment
        • 16.5.1.2.2. By Disease
        • 16.5.1.2.3. By Cause
        • 16.5.1.2.4. By Distribution Channel
    • 16.5.2. Thailand Market Analysis
      • 16.5.2.1. . Introduction
      • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.2.2.1. By Treatment
        • 16.5.2.2.2. By Disease
        • 16.5.2.2.3. By Cause
        • 16.5.2.2.4. By Distribution Channel
    • 16.5.3. Indonesia Market Analysis
      • 16.5.3.1. Introduction
      • 16.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.3.2.1. By Treatment
        • 16.5.3.2.2. By Disease
        • 16.5.3.2.3. By Cause
        • 16.5.3.2.4. By Distribution Channel
    • 16.5.4. Malaysia Market Analysis
      • 16.5.4.1. Introduction
      • 16.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.4.2.1. By Treatment
        • 16.5.4.2.2. By Disease
        • 16.5.4.2.3. By Cause
        • 16.5.4.2.4. By Distribution Channel
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis

17. East Asia Market Outlook, 2019 - 2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Treatment
    • 17.3.3. By Disease
    • 17.3.4. By Cause
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Treatment
    • 17.4.3. By Disease
    • 17.4.4. By Cause
    • 17.4.5. By Distribution Channel
  • 17.5. Country Level Analysis & Forecast
    • 17.5.1. China Market Analysis
      • 17.5.1.1. . Introduction
      • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.1.2.1. By Treatment
        • 17.5.1.2.2. By Disease
        • 17.5.1.2.3. By Cause
        • 17.5.1.2.4. By Distribution Channel
    • 17.5.2. Japan Market Analysis
      • 17.5.2.1. Introduction
      • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.2.2.1. By Treatment
        • 17.5.2.2.2. By Disease
        • 17.5.2.2.3. By Cause
        • 17.5.2.2.4. By Distribution Channel
    • 17.5.3. South Korea Market Analysis
      • 17.5.3.1. Introduction
      • 17.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.3.2.1. By Treatment
        • 17.5.3.2.2. By Disease
        • 17.5.3.2.3. By Cause
        • 17.5.3.2.4. By Distribution Channel
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis

18. Oceania Market Outlook, 2019 - 2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Treatment
    • 18.3.3. By Disease
    • 18.3.4. By Cause
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Treatment
    • 18.4.3. By Disease
    • 18.4.4. By Cause
    • 18.4.5. By Distribution Channel
  • 18.5. Country Level Analysis & Forecast
    • 18.5.1. Australia Market Analysis
      • 18.5.1.1. . Introduction
      • 18.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.1.2.1. By Treatment
        • 18.5.1.2.2. By Disease
        • 18.5.1.2.3. By Cause
        • 18.5.1.2.4. By Distribution Channel
    • 18.5.2. New Zealand Market Analysis
      • 18.5.2.1. Introduction
      • 18.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.2.2.1. By Treatment
        • 18.5.2.2.2. By Disease
        • 18.5.2.2.3. By Cause
        • 18.5.2.2.4. By Distribution Channel
  • 18.6. Market Trends
  • 18.7. Key Market Participants - Intensity Mapping
  • 18.8. Drivers and Restraints - Impact Analysis

19. Middle East and Africa Market Outlook, 2019 - 2032

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
  • 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkiye
      • 19.3.1.3. Northern Africa
      • 19.3.1.4. South Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Treatment
    • 19.3.3. By Disease
    • 19.3.4. By Cause
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Treatment
    • 19.4.3. By Disease
    • 19.4.4. By Cause
    • 19.4.5. By Distribution Channel
  • 19.5. Country Level Analysis & Forecast
    • 19.5.1. GCC Countries Market Analysis
      • 19.5.1.1. . Introduction
      • 19.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.5.1.2.1. By Treatment
        • 19.5.1.2.2. By Disease
        • 19.5.1.2.3. By Cause
        • 19.5.1.2.4. By Distribution Channel
    • 19.5.2. Turkiye Market Analysis
      • 19.5.2.1. Introduction
      • 19.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.5.2.2.1. By Treatment
        • 19.5.2.2.2. By Disease
        • 19.5.2.2.3. By Cause
        • 19.5.2.2.4. By Distribution Channel
    • 19.5.3. Northern Africa Market Analysis
      • 19.5.3.1. Introduction
      • 19.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.5.3.2.1. By Treatment
        • 19.5.3.2.2. By Disease
        • 19.5.3.2.3. By Cause
        • 19.5.3.2.4. By Distribution Channel
    • 19.5.4. South Africa Market Analysis
      • 19.5.4.1. Introduction
      • 19.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.5.4.2.1. By Treatment
        • 19.5.4.2.2. By Disease
        • 19.5.4.2.3. By Cause
        • 19.5.4.2.4. By Distribution Channel
  • 19.6. Market Trends
  • 19.7. Key Market Participants - Intensity Mapping
  • 19.8. Drivers and Restraints - Impact Analysis

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Branding and Promotional Strategies
  • 21.3. Key Development Analysis
  • 21.4. Competition Deep Dive
    • 21.4.1. Allergan, Inc
      • 21.4.1.1. Overview
      • 21.4.1.2. Product Portfolio
      • 21.4.1.3. Key Financials
      • 21.4.1.4. Sales Footprint
      • 21.4.1.5. Strategy Overview
        • 21.4.1.5.1. Marketing Strategy
        • 21.4.1.5.2. Product Strategy
        • 21.4.1.5.3. Channel Strategy
    • 21.4.2. Novartis AG
      • 21.4.2.1. Overview
      • 21.4.2.2. Product Portfolio
      • 21.4.2.3. Key Financials
      • 21.4.2.4. Sales Footprint
      • 21.4.2.5. Strategy Overview
        • 21.4.2.5.1. Marketing Strategy
        • 21.4.2.5.2. Product Strategy
        • 21.4.2.5.3. Channel Strategy
    • 21.4.3. Bausch Health Inc.
      • 21.4.3.1. Overview
      • 21.4.3.2. Product Portfolio
      • 21.4.3.3. Key Financials
      • 21.4.3.4. Sales Footprint
      • 21.4.3.5. Strategy Overview
        • 21.4.3.5.1. Marketing Strategy
        • 21.4.3.5.2. Product Strategy
        • 21.4.3.5.3. Channel Strategy
    • 21.4.4. AbbVie Inc.
      • 21.4.4.1. Overview
      • 21.4.4.2. Product Portfolio
      • 21.4.4.3. Key Financials
      • 21.4.4.4. Sales Footprint
      • 21.4.4.5. Strategy Overview
        • 21.4.4.5.1. Marketing Strategy
        • 21.4.4.5.2. Product Strategy
        • 21.4.4.5.3. Channel Strategy
    • 21.4.5. Tarsier Pharma
      • 21.4.5.1. Overview
      • 21.4.5.2. Product Portfolio
      • 21.4.5.3. Key Financials
      • 21.4.5.4. Sales Footprint
      • 21.4.5.5. Strategy Overview
        • 21.4.5.5.1. Marketing Strategy
        • 21.4.5.5.2. Product Strategy
        • 21.4.5.5.3. Channel Strategy
    • 21.4.6. EyeGate Pharmaceuticals, Inc.
      • 21.4.6.1. Overview
      • 21.4.6.2. Product Portfolio
      • 21.4.6.3. Key Financials
      • 21.4.6.4. Sales Footprint
      • 21.4.6.5. Strategy Overview
        • 21.4.6.5.1. Marketing Strategy
        • 21.4.6.5.2. Product Strategy
        • 21.4.6.5.3. Channel Strategy
    • 21.4.7. Alimera Science Inc
      • 21.4.7.1. Overview
      • 21.4.7.2. Product Portfolio
      • 21.4.7.3. Key Financials
      • 21.4.7.4. Sales Footprint
      • 21.4.7.5. Strategy Overview
        • 21.4.7.5.1. Marketing Strategy
        • 21.4.7.5.2. Product Strategy
        • 21.4.7.5.3. Channel Strategy
    • 21.4.8. Eyepoint Pharmaceutical
      • 21.4.8.1. Overview
      • 21.4.8.2. Product Portfolio
      • 21.4.8.3. Key Financials
      • 21.4.8.4. Sales Footprint
      • 21.4.8.5. Strategy Overview
        • 21.4.8.5.1. Marketing Strategy
        • 21.4.8.5.2. Product Strategy
        • 21.4.8.5.3. Channel Strategy
    • 21.4.9. Santen Pharmaceuticals
      • 21.4.9.1. Overview
      • 21.4.9.2. Product Portfolio
      • 21.4.9.3. Key Financials
      • 21.4.9.4. Sales Footprint
      • 21.4.9.5. Strategy Overview
        • 21.4.9.5.1. Marketing Strategy
        • 21.4.9.5.2. Product Strategy
        • 21.4.9.5.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology